Jubilant Life Sciences, a global pharmaceutical and life sciences company, received ANDA approval for its Celecoxib capsules. The stock of Jubilant Life Sciences is trading at 832 levels, reporting 0.28% loss from previous close.
The company engaged in manufacturing of pharma, life science ingredients and drug discovery solutions received approval for the generic version of Celebrex, Celecoxib capsules of 50mg, 100mg, 200mg and 400mg. The capsules are used for treatment of Osteoarthritis and Rheumatoid Arthritis.
Till December ended 2016, the company had 73 ANDAs for oral solids filed in the US of which 49 have been approved and 24 are pending. Earlier in February 2017, the company had received ANDA approval for its Itraconazole capsules used in treatment of fungal infections.